These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 19061215)

  • 21. Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors.
    Reis-Alves SC; Traina F; Metze K; Lorand-Metze I
    Diagn Pathol; 2015 Apr; 10():44. PubMed ID: 25924846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiparametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia.
    Suárez L; Vidriales B; García-Laraña J; López A; Martínez R; Martín-Reina V; Tormo M; González-San Miguel JD; Lavilla E; García-Boyero R; Orfao A; San Miguel JF;
    Haematologica; 2001 Dec; 86(12):1287-95. PubMed ID: 11726321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].
    Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
    Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunophenotype of myeloid cells in myelodysplastic syndromes and its clinical implications.
    Shao Z; Chen G; Lin Z; Zhang Y; Hao Y; Chu Y; Zheng Y; Qian L; Yang T; Yang C; Feng B
    Chin Med J (Engl); 1998 Jan; 111(1):28-31. PubMed ID: 10322648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic potential of CD34+ cell antigen expression in myelodysplastic syndromes.
    De Smet D; Trullemans F; Jochmans K; Renmans W; Smet L; Heylen O; Bael AM; Schots R; Leus B; De Waele M
    Am J Clin Pathol; 2012 Nov; 138(5):732-43. PubMed ID: 23086775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical implications of immunophenotypic abnormalities of bone marrow myeloid cell compartment in myelodysplastic syndromes.
    Marisavljevic D; Kraguljac-Kurtovic N
    J BUON; 2010; 15(4):746-52. PubMed ID: 21229640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis.
    Klobusicka M; Kusenda J; Babusikova O
    Neoplasma; 2005; 52(3):211-8. PubMed ID: 15875082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
    Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
    Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes.
    Falco P; Levis A; Stacchini A; Ciriello MM; Geuna M; Notari P; Omedè P; Pautasso M; Prato G; Strola G; Gioia D; Bonferroni M; Cametti G; Ferrero D; Freilone R; Gaidano G; Marinone C; Marmont F; Pollio B; Salvi F; Saglio G; Girotto M;
    Eur J Haematol; 2011 Nov; 87(5):409-18. PubMed ID: 21711395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
    Zelezníková T; Babusíková O
    Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes.
    Sandes AF; Kerbauy DM; Matarraz S; Chauffaille Mde L; López A; Orfao A; Yamamoto M
    Cytometry B Clin Cytom; 2013 May; 84(3):157-66. PubMed ID: 23475532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
    Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes.
    Xu F; Li X; Wu L; He Q; Zhang Z; Chang C
    Br J Haematol; 2010 May; 149(4):587-97. PubMed ID: 20331463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Study on the immunophenotype of myeloid cells in myelodysplastic syndromes and its clinical implications].
    Shao Z; Chen G; Lin Z; Zhang Y; Hao Y; Chu Y; Qian L; Yang T; Yang C; Feng B
    Zhonghua Xue Ye Xue Za Zhi; 1997 Feb; 18(2):80-3. PubMed ID: 15622783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The value of dot plot patterns and leukemia-associated phenotypes in AML diagnosis by multiparameter flow cytometry.
    Zelezníková T; Babusíková O
    Neoplasma; 2005; 52(6):517-22. PubMed ID: 16284699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunophenotypic features of granulocytes, monocytes, and blasts in myelodysplastic syndromes.
    Moon HW; Huh JW; Lee M; Hong KS; Chung WS
    Korean J Lab Med; 2010 Apr; 30(2):97-104. PubMed ID: 20445324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Altered responses of purified blast cells from the myelodysplastic syndromes to colony-stimulating factors in vitro: comparison with normal blast cells.
    Tohyama K; Ueda T; Yoshida Y; Nakamura T
    Exp Hematol; 1994 Jul; 22(7):539-45. PubMed ID: 7516887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Abnormalities of CD34+ cells differentiation and bone marrow cell cycle in myelodysplastic syndrome].
    Li LJ; Fu R; Shao ZH; Wang HQ; Yue LZ; Ruan EB; Liu H; Wang J; Wang HL
    Zhonghua Nei Ke Za Zhi; 2010 Nov; 49(11):963-6. PubMed ID: 21211213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD34/CD117 positivity in assessment of prognosis in children with myelodysplastic syndrome.
    Tavil B; Cetin M; Tuncer M
    Leuk Res; 2006 Feb; 30(2):222-4. PubMed ID: 16098587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro growth modulation by L-ascorbic acid of colony-forming cells from bone marrow of patients with myelodysplastic syndromes.
    Park CH; Kimler BF; Bodensteiner D; Lynch SR; Hassanein RS
    Cancer Res; 1992 Aug; 52(16):4458-66. PubMed ID: 1643638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.